Search Results

Surmodics, Inc. announced it has been awarded a group purchasing agreement for thrombectomy products with Premier, Inc. Effective June 1, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Surmodics Pounce™ and Pounce™ Venous Thrombectomy Systems.

Surmodics, Inc. today announced that management will participate in the following upcoming investor conferences.

Surmodics, Inc today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday, May 1.

Surmodics, Inc. today announced that it has entered into a definitive agreement to be acquired by GTCR, a leading private equity firm with a long track record of investment expertise across healthcare and healthcare technology.

Surmodics, Inc., a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, reported financial results for its second quarter ended March 31, 2024, and updated financial guidance for its fiscal year ending September 30, 2024.

Surmodics, Inc. will hold its Annual Meeting of Shareholders on Thursday, February 8, at 4 p.m. CT (5 p.m. ET), as a virtual meeting.

Surmodics, Inc. today announced that first quarter of fiscal year 2024 financial results will be released before the market opens on Thursday, February 1.

Surmodics, Inc. today reported financial results for its first quarter ended December 31, 2023, and updated its financial guidance for fiscal year ending September 30, 2024.